Wednesday, September 21, 2011
Santarus Inc., of San Diego, said analysis of top-line safety data from a 12-month extended-use study in patients treated daily with either budesonide MMX 6 mg or placebo showed a similar frequency of treatment-related adverse events for both groups (21 percent to 21.3 percent) and no clinically meaningful differences in the numbers of patients with abnormal bone mineral density scans at baseline and end of the study between the budesonide and placebo groups.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.